NIH-funded research NIH-funded research

Developing new vaccine adjuvants to enhance immune responses

Official title: BASE AWARD

Funded at University of Maryland Baltimore County · NIH-10935816 · Data updated 2026-11-12

This study is looking to make better vaccines by finding new ingredients that help boost your immune response, and it's designed for adults and older people to see how safe and effective these new combinations can be.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionUniversity of Maryland Baltimore County
NIH-funded
Lab location1 site (Baltimore, United States)
Project startSeptember 30, 2023
Project endSeptember 29, 2028
Funding year2023
Award (this year)$1,896,671
NIH project number75N93023C00046-0-9999-1
Project IDNIH-10935816 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research include immunocompetent adults and elderly individuals who may benefit from enhanced vaccine responses.

Less likely to help

Patients with compromised immune systems or those who are not eligible for vaccination may not receive benefits from this research.

What this research studies

This research focuses on creating next-generation vaccines by identifying effective target antigens and adjuvants that enhance immune responses. Using a technology called Bacterial Enzymatic Combinatorial Chemistry (BECC), the study aims to produce synthetic compounds that stimulate the immune system through specific receptors. The research will evaluate the safety and effectiveness of these new adjuvants in combination with established vaccine antigens, targeting both adult and elderly populations. The goal is to improve vaccine efficacy and longevity of immune responses.

Why it matters

Potential benefit: If successful, this research could lead to more effective vaccines that provide better protection against infections, especially for vulnerable populations.

How similar studies have gone: Previous research has shown promise in using similar adjuvant technologies to enhance vaccine responses, indicating potential for success in this approach.

Where this research is happening

  • University of Maryland Baltimore County
    Baltimore, United States
    Active

Researchers

  • Principal investigator: Sorenson, Gregory — University of Maryland Baltimore County
  • Study coordinator: Sorenson, Gregory

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.